ELOXX PHARMACEUTICALS, INC. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of $72.67 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2017-11-14
- ELOXX PHARMACEUTICALS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-09-30 was $72.67K.
- ELOXX PHARMACEUTICALS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2017-06-30 was $799.11K.
- ELOXX PHARMACEUTICALS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2017 was $743.56K.
- ELOXX PHARMACEUTICALS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2016 was $0.00.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $72.67K 10-Q · filed 2017-11-14 | $871.78K derived: sum of 2 quarters · filed 2017-11-14 | ||
| 2017-06-30 | $799.11K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $743.56K 10-K · filed 2017-10-13 | ||
| 2017-03-31 | -$55.55K 10-Q · filed 2017-05-22 | |||
| 2016-06-30 | $0.00 10-K · filed 2017-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |